Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Dementia"" wg kryterium: Temat


Tytuł :
The positive effect of spermidine in older adults suffering from dementia : First results of a 3-month trial.
Autorzy :
Pekar T; Biomedical Science, University of Applied Sciences Wiener Neustadt, Johannes-Gutenberg-Str. 3, 2700, Wiener Neustadt, Austria. .
Bruckner K; Biomedical Science, University of Applied Sciences Wiener Neustadt, Johannes-Gutenberg-Str. 3, 2700, Wiener Neustadt, Austria.
Pauschenwein-Frantsich S; Biomedical Science, University of Applied Sciences Wiener Neustadt, Johannes-Gutenberg-Str. 3, 2700, Wiener Neustadt, Austria.
Gschaider A; Biomedical Science, University of Applied Sciences Wiener Neustadt, Johannes-Gutenberg-Str. 3, 2700, Wiener Neustadt, Austria.
Oppliger M; Biomedical Science, University of Applied Sciences Wiener Neustadt, Johannes-Gutenberg-Str. 3, 2700, Wiener Neustadt, Austria.
Willesberger J; Biomedical Science, University of Applied Sciences Wiener Neustadt, Johannes-Gutenberg-Str. 3, 2700, Wiener Neustadt, Austria.
Ungersbäck P; Biomedical Science, University of Applied Sciences Wiener Neustadt, Johannes-Gutenberg-Str. 3, 2700, Wiener Neustadt, Austria.
Wendzel A; Gepflegt Wohnen GmbH, 182, 8412, Allerheiligen bei Wildon, Austria.
Kremer A; Privatklinik Rudolfinerhaus GmbH, Billrothstr. 78, 1190, Vienna, Austria.
Flak W; Federal Office for Viticulture, Gölbeszeile 1, 7000, Eisenstadt, Austria.
Wantke F; FAZ Floridsdorfer Allergiezentrum, Pius-Parsch-Platz 1/3, 1210, Vienna, Austria.
Jarisch R; FAZ Floridsdorfer Allergiezentrum, Pius-Parsch-Platz 1/3, 1210, Vienna, Austria.
Pokaż więcej
Źródło :
Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2021 May; Vol. 133 (9-10), pp. 484-491. Date of Electronic Publication: 2020 Nov 19.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Alzheimer Disease*
Dementia*/drug therapy
Aged ; Aged, 80 and over ; Aging ; Humans ; Memory ; Mental Status and Dementia Tests ; Middle Aged ; Spermidine
Czasopismo naukowe
Tytuł :
Cognitive assessment tools for mild cognitive impairment screening.
Autorzy :
Zhuang L; Department of Neurology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Yang Y; Department of Nursing, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Gao J; Brain and Mind Centre, Central Clinical School, the University of Sydney, Sydney, Australia. .
Pokaż więcej
Źródło :
Journal of neurology [J Neurol] 2021 May; Vol. 268 (5), pp. 1615-1622. Date of Electronic Publication: 2019 Aug 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cognitive Dysfunction*/diagnosis
Dementia*
Aged ; Cognition ; Humans ; Mass Screening ; Mental Status and Dementia Tests ; Neuropsychological Tests ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Accuracy of the Montreal Cognitive Assessment in Detecting Mild Cognitive Impairment and Dementia in the Rural African Population.
Autorzy :
Masika GM; The Nethersole School of Nursing, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong.; Department of Nursing and Midwifery, College of Health Sciences, University of Dodoma, Dodoma, Tanzania.
Yu DSF; The Nethersole School of Nursing, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong.; School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
Li PWC; The Nethersole School of Nursing, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong.; School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
Pokaż więcej
Źródło :
Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists [Arch Clin Neuropsychol] 2021 Apr 21; Vol. 36 (3), pp. 371-380.
Typ publikacji :
Journal Article
MeSH Terms :
Cognitive Dysfunction*/diagnosis
Dementia*/diagnosis
Aged ; Humans ; Mental Status and Dementia Tests ; Neuropsychological Tests ; Reproducibility of Results ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Diagnostic accuracy of the Clinical Dementia Rating Scale for detecting mild cognitive impairment and dementia: A bivariate meta-analysis.
Autorzy :
Huang HC; School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, ROC.
Tseng YM; School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, ROC.
Chen YC; Department of Neurology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC.
Chen PY; Department of Neurosurgery, Chang Gung Memorial Hospital, Keelung, Taiwan, ROC.; School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ROC.
Chiu HY; School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan, ROC.; Research Center of Sleep Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC.
Pokaż więcej
Źródło :
International journal of geriatric psychiatry [Int J Geriatr Psychiatry] 2021 Feb; Vol. 36 (2), pp. 239-251. Date of Electronic Publication: 2020 Oct 09.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms :
Cognitive Dysfunction*/diagnosis
Dementia*/diagnosis
Aged ; Humans ; Mental Status and Dementia Tests ; Neuropsychological Tests ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Validation of the Kimberley Indigenous Cognitive Assessment short form (KICA-screen) for telehealth.
Autorzy :
Russell S; College of Medicine and Dentistry, James Cook University, Australia.; Cairns and Hinterland Hospital and Health Service, Australia.
Quigley R; College of Medicine and Dentistry, James Cook University, Australia.; Cairns and Hinterland Hospital and Health Service, Australia.
Strivens E; College of Medicine and Dentistry, James Cook University, Australia.; Cairns and Hinterland Hospital and Health Service, Australia.
Miller G; College of Medicine and Dentistry, James Cook University, Australia.; Cairns and Hinterland Hospital and Health Service, Australia.
Norrie J; Cairns and Hinterland Hospital and Health Service, Australia.
Craig D; Cairns and Hinterland Hospital and Health Service, Australia.
Jordan J; Cairns and Hinterland Hospital and Health Service, Australia.
Muller R; Centre for Chronic Disease Prevention, James Cook University, Australia.
Pokaż więcej
Źródło :
Journal of telemedicine and telecare [J Telemed Telecare] 2021 Jan; Vol. 27 (1), pp. 54-58. Date of Electronic Publication: 2019 Jul 08.
Typ publikacji :
Comparative Study; Journal Article; Validation Study
MeSH Terms :
Culturally Competent Care*/ethnology
Culturally Competent Care*/methods
Mass Screening*/methods
Mental Status and Dementia Tests*
Oceanic Ancestry Group*
Telemedicine*
Dementia/*diagnosis
Delivery of Health Care/methods ; Dementia/ethnology ; Health Status ; Humans ; Indigenous Peoples ; Patient Care/methods ; Prospective Studies ; Videoconferencing
Czasopismo naukowe
Tytuł :
Mental representations of daily activities throughout the course of dementia.
Autorzy :
Ross SD; German Centre for Neurodegenerative Diseases (DZNE), Research Group Psychosocial Epidemiology and Public Health, Greifswald, Germany.
Rodriguez FS; German Centre for Neurodegenerative Diseases (DZNE), Research Group Psychosocial Epidemiology and Public Health, Greifswald, Germany.; Centre for Cognitive Science, University of Kaiserslautern, Germany.; Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany.
Pokaż więcej
Źródło :
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society [Psychogeriatrics] 2021 Jan; Vol. 21 (1), pp. 3-13. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :
Journal Article
MeSH Terms :
Cognitive Dysfunction*
Dementia*
Activities of Daily Living ; Humans ; Mental Status and Dementia Tests
Czasopismo naukowe
Tytuł :
Neural correlates of naming errors across different neurodegenerative diseases: An FDG-PET study.
Autorzy :
Catricalà E; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Polito C; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Presotto L; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Esposito V; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Sala A; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Conca F; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Gasparri C; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Berti V; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Filippi M; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Pupi A; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Sorbi S; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Iannaccone S; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Magnani G; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Cappa SF; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy. .
Perani D; From the Faculty of Psychology (E.C., F.C., C.G., S.F.C.), Institute for Advanced Studies, IUSS, Pavia; Nuclear Medicine Unit (C.P., V.B., A.P.), Department of Experimental and Clinical Biomedical Sciences, and NEUROFARBA, Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence; Nuclear Medicine Unit (L.P., A.S., D.P.), IRCCS San Raffaele Hospital, Milan; Faculty of Psychology (V.E., A.S., D.P.), Vita-Salute San Raffaele University, Milan; Department of Neurology and INSPE (M.F., G.M.), San Raffaele Scientific Institute, Milan; Clinical Neuroscience Department (S.I.), San Raffaele Turro Hospital, Milan; IRCCS Fondazione Don Carlo Gnocchi (S.S.), Florence, and IRCCS Fondazione Istituto Neurologico Casimiro Mondino (S.F.C.), Pavia, Italy.
Pokaż więcej
Źródło :
Neurology [Neurology] 2020 Nov 17; Vol. 95 (20), pp. e2816-e2830. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article
MeSH Terms :
Connectome*
Dementia*/diagnostic imaging
Dementia*/metabolism
Dementia*/physiopathology
Language*
Neurodegenerative Diseases*/diagnostic imaging
Neurodegenerative Diseases*/metabolism
Neurodegenerative Diseases*/physiopathology
Occipital Lobe*/diagnostic imaging
Occipital Lobe*/metabolism
Occipital Lobe*/physiopathology
Positron-Emission Tomography*
Temporal Lobe*/diagnostic imaging
Temporal Lobe*/metabolism
Temporal Lobe*/physiopathology
Aged ; Aged, 80 and over ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/metabolism ; Alzheimer Disease/physiopathology ; Aphasia, Primary Progressive/diagnostic imaging ; Aphasia, Primary Progressive/metabolism ; Aphasia, Primary Progressive/physiopathology ; Female ; Fluorodeoxyglucose F18 ; Frontotemporal Dementia/diagnostic imaging ; Frontotemporal Dementia/metabolism ; Frontotemporal Dementia/physiopathology ; Humans ; Male ; Pattern Recognition, Visual/physiology ; Retrospective Studies ; Semantics ; Speech/physiology ; Supranuclear Palsy, Progressive/diagnostic imaging ; Supranuclear Palsy, Progressive/metabolism ; Supranuclear Palsy, Progressive/physiopathology
Czasopismo naukowe
Tytuł :
Efficacy and safety of Buyang Huanwu-Tang (Boyang Hwano-Tang) in patients with vascular dementia: A protocol of systematic review and meta analysis.
Autorzy :
Kook HJ; College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea.
Kim DW; Department of Neuropsychiatry of Korean Medicine, Pohang Korean Medicine Hospital, Daegu Haany University, Pohang.
Kim JY; Department of Oriental Neuropsychiatry, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea.
Kim SH; Department of Neuropsychiatry of Korean Medicine, Pohang Korean Medicine Hospital, Daegu Haany University, Pohang.
Jung IC; Department of Oriental Neuropsychiatry, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 May 28; Vol. 100 (21), pp. e25886.
Typ publikacji :
Journal Article
MeSH Terms :
Cognitive Dysfunction/*drug therapy
Dementia, Vascular/*drug therapy
Drugs, Chinese Herbal/*administration & dosage
Cognitive Dysfunction/diagnosis ; Cognitive Dysfunction/etiology ; Dementia, Vascular/complications ; Dementia, Vascular/diagnosis ; Drugs, Chinese Herbal/adverse effects ; Humans ; Mental Status and Dementia Tests/statistics & numerical data ; Meta-Analysis as Topic ; Randomized Controlled Trials as Topic ; Systematic Reviews as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Value-Generating Exploratory Trials in Neurodegenerative Dementias.
Autorzy :
Friedman LG; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
McKeehan N; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Hara Y; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Cummings JL; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Matthews DC; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Zhu J; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Mohs RC; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Wang D; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Hendrix SB; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Quintana M; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Schneider LS; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Grundman M; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Dickson SP; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Feldman HH; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Jaeger J; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Finger EC; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Ryan JM; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Niehoff D; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Dickinson SL; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Markowitz JT; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Owen M; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Travaglia A; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA.
Fillit HM; From the Alzheimer's Drug Discovery Foundation (L.G.F., N.M., Y.H., M.O., A.T., H.M.F.), New York; Chambers-Grundy Center for Transformative Neuroscience (J.L.C.), Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas; ADM Diagnostics (D.C.M.), Inc. Northbrook, IL; Servier Pharmaceuticals (J.Z.), Boston, MA; Global Alzheimer's Platform Foundation (R.C.M.), Washington, DC; AgeneBio (R.C.M.), Inc. Baltimore, MD; AbbVie Inc. (D.W.), North Chicago, IL; Pentara Corporation (S.B.H., S.P.D.), Salt Lake City, UT; Berry Consultants (M.Q.), Austin TX; Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Global R&D Partners (M.G.), LLC, University of California, San Diego, La Jolla; Department of Neurosciences (H.H.F.), University of California, San Diego, La Jolla; Albert Einstein College of Medicine (J.J.), Bronx, NY; CognitionMetrics (J.J.), LLC; Department of Clinical Neurological Sciences and Robarts Research Institute (E.C.F.), Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (E.C.F.), Lawson Health Research Institute, St. Josephs Health Care, London, Ontario, Canada; Rodin Therapeutics (J.M.R.), Boston, MA; Association for Frontotemporal Degeneration (D.N., S.L.-J.D.), Radnor, PA; and Modus Outcomes LLP (J.T.M.), Cambridge, MA. .
Pokaż więcej
Źródło :
Neurology [Neurology] 2021 May 18; Vol. 96 (20), pp. 944-954. Date of Electronic Publication: 2021 Mar 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Alzheimer Disease/*drug therapy
Clinical Trials as Topic/*methods
Drug Development/*methods
Frontotemporal Dementia/*drug therapy
Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Dementia/drug therapy ; Humans ; Neurodegenerative Diseases/drug therapy ; Outcome Assessment, Health Care ; Proof of Concept Study ; Research Design ; Treatment Failure ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Hearing and dementia: from ears to brain.
Autorzy :
Johnson JCS; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.
Marshall CR; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.; Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
Weil RS; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.; Movement Disorders Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.; Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology, University College London, London, UK.
Bamiou DE; UCL Ear Institute and UCL/UCLH Biomedical Research Centre, National Institute for Health Research, University College London, London, UK.
Hardy CJD; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.
Warren JD; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.
Pokaż więcej
Źródło :
Brain : a journal of neurology [Brain] 2021 Mar 03; Vol. 144 (2), pp. 391-401.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Dementia/*physiopathology
Hearing Loss/*physiopathology
Aged ; Aged, 80 and over ; Alzheimer Disease/complications ; Auditory Perception/physiology ; Brain/physiopathology ; Cognitive Dysfunction/complications ; Comorbidity ; Dementia/complications ; Frontotemporal Dementia/complications ; Hearing/physiology ; Hearing Loss/complications ; Humans ; Lewy Body Disease/complications ; Middle Aged
Czasopismo naukowe
Tytuł :
Covid-19 in dementia: an insidious pandemic.
Autorzy :
Yao JS; Hoboken University Medical Center, Hoboken, NJ 07030, USA.
Dee EC; Harvard Medical School, Boston, MA, USA.
Milazzo C; Hoboken University Medical Center, Hoboken, NJ 07030, USA.
Jurado J; Hoboken University Medical Center, Hoboken, NJ 07030, USA.
Paguio JA; Hoboken University Medical Center, Hoboken, NJ 07030, USA.
Pokaż więcej
Źródło :
Age and ageing [Age Ageing] 2020 Aug 24; Vol. 49 (5), pp. 713-715.
Typ publikacji :
Letter
MeSH Terms :
Coronavirus Infections*/epidemiology
Coronavirus Infections*/psychology
Coronavirus Infections*/therapy
Dementia*/diagnosis
Dementia*/epidemiology
Dementia*/physiopathology
Dementia*/therapy
Pandemics*
Patient Care Management*/ethics
Patient Care Management*/methods
Pneumonia, Viral*/epidemiology
Pneumonia, Viral*/psychology
Pneumonia, Viral*/therapy
Betacoronavirus/*isolation & purification
Hospitalization/*statistics & numerical data
Advance Directives/ethics ; Advance Directives/statistics & numerical data ; Aged, 80 and over ; COVID-19 ; Clinical Decision-Making/ethics ; Comorbidity ; Female ; Hospital Mortality ; Humans ; Male ; Mental Status and Dementia Tests ; Nursing Homes/statistics & numerical data ; SARS-CoV-2 ; Severity of Illness Index ; United States/epidemiology
Opinia redakcyjna
Tytuł :
Digital Screening for Cognitive Impairment - A Proof of Concept Study.
Autorzy :
Bloniecki V; Victor Bloniecki, Karolinska Institute, Karolinska Uinversity Hospital, Eugeniavägen 3, SE-17176, Stockholm, Sweden. Tel.: +46 70-726 82 20; Email: .
Hagman G
Ryden M
Kivipelto M
Pokaż więcej
Źródło :
The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2021; Vol. 8 (2), pp. 127-134.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Mental Status and Dementia Tests*
Cognitive Dysfunction/*diagnosis
Dementia/*diagnosis
Memory/*physiology
Adult ; Aged ; Female ; Geriatric Assessment/methods ; Humans ; Male ; Middle Aged ; Neuropsychological Tests ; Proof of Concept Study ; Reproducibility of Results ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
The power of the Functional Activities Questionnaire for screening dementia in rural-dwelling older adults at high-risk of cognitive impairment.
Autorzy :
Yin L; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Ren Y; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Wang X; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Li Y; School of Public Health, Shandong University, Jinan, China.
Hou T; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Liu K; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Cong L; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Zhang Q; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Wang Y; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Jiang Z; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Du Y; Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Pokaż więcej
Źródło :
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society [Psychogeriatrics] 2020 Jul; Vol. 20 (4), pp. 427-436. Date of Electronic Publication: 2020 Feb 24.
Typ publikacji :
Journal Article
MeSH Terms :
Cognitive Dysfunction*/diagnosis
Dementia*/diagnosis
Mass Screening*
Aged ; Humans ; Mental Status and Dementia Tests ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Is Qi Fu Yin effective in clinical treatment of dementia?: A meta-analysis of 697 patients.
Autorzy :
Wang L; College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan.; Institute of Pharmacology, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian.
Qiao P; Institute of Pharmacology, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian.
Yue L; Institute of Pharmacology, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian.
Sun R; College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan.; Institute of Advanced Medical Sciences.; The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Feb 05; Vol. 100 (5), pp. e24526.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Dementia/*drug therapy
Drugs, Chinese Herbal/*therapeutic use
Activities of Daily Living ; Drugs, Chinese Herbal/administration & dosage ; Drugs, Chinese Herbal/adverse effects ; Humans ; Mental Status and Dementia Tests ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Incidence and distribution of subtypes of early-onset dementia in Japan: A nationwide analysis based on annual performance reports of the Medical Centers for Dementia.
Autorzy :
Edahiro A; Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Miyamae F; Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Taga T; Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Sugiyama M; Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Kikuchi K; Research Team for Human Care, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Okamura T; Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Awata S; Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Pokaż więcej
Źródło :
Geriatrics & gerontology international [Geriatr Gerontol Int] 2020 Nov; Vol. 20 (11), pp. 1050-1055. Date of Electronic Publication: 2020 Sep 28.
Typ publikacji :
Journal Article
MeSH Terms :
Alzheimer Disease/*epidemiology
Dementia, Vascular/*epidemiology
Frontotemporal Dementia/*epidemiology
Lewy Body Disease/*epidemiology
Adolescent ; Adult ; Dementia/classification ; Female ; Humans ; Incidence ; Japan/epidemiology ; Male ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł :
Prevalence and subtype distribution of early-onset dementia in Japan.
Autorzy :
Awata S; Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Edahiro A; Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Arai T; Department of Psychiatry, Division of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Ikeda M; Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan.
Ikeuchi T; Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Kawakatsu S; Department of Neuropsychiatry, Aizu Medical Center, Fukushima Medical University, Aizu, Japan.
Konagaya Y; Division of Research, Obu Dementia Care and Training Center, Obu, Japan.
Miyanaga K; Yukiguni-Yamato Hospital, Niigata, Japan.
Ota H; Advanced Research Center for Geriatric and Gerontology, Akita University, Akita, Japan.
Suzuki K; Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University School of Medicine, Sendai, Japan.
Tanimukai S; Department of Comprehensive Community Care for Elderly, Nursing and Health Science, Graduate School of Medicine, Ehime University, Toon, Japan.
Utsumi K; Department of Psychiatry, Sunagawa City Medical Center, Sunagawa, Japan.
Kakuma T; Biostatistics Center, Kurume University School of Medicine, Kurume, Japan.
Pokaż więcej
Źródło :
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society [Psychogeriatrics] 2020 Nov; Vol. 20 (6), pp. 817-823. Date of Electronic Publication: 2020 Aug 19.
Typ publikacji :
Journal Article
MeSH Terms :
Dementia/*classification
Dementia/*epidemiology
Adolescent ; Adult ; Age of Onset ; Alzheimer Disease/classification ; Alzheimer Disease/epidemiology ; Dementia, Vascular/classification ; Dementia, Vascular/epidemiology ; Female ; Health Surveys ; Humans ; Japan/epidemiology ; Male ; Middle Aged ; Prevalence ; Young Adult
Czasopismo naukowe
Tytuł :
Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia.
Autorzy :
Ricci M; Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Cimini A; Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Chiaravalloti A; Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.; Nuclear Medicine Section, IRCCS Neuromed, 86077 Pozzilli, Italy.
Filippi L; Nuclear Medicine Section, 'Santa Maria Goretti' Hospital, 04100 Latina, Italy.
Schillaci O; Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.; Nuclear Medicine Section, IRCCS Neuromed, 86077 Pozzilli, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Oct 11; Vol. 21 (20). Date of Electronic Publication: 2020 Oct 11.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Neuroimaging*/methods
Positron-Emission Tomography*/methods
Precision Medicine*/methods
Dementia/*diagnosis
Dementia/*etiology
Nerve Degeneration/*complications
Alzheimer Disease/complications ; Alzheimer Disease/diagnosis ; Alzheimer Disease/etiology ; Brain/diagnostic imaging ; Brain/pathology ; Brain/physiopathology ; Diagnosis, Differential ; Frontotemporal Dementia/diagnosis ; Frontotemporal Dementia/etiology ; Humans ; Magnetic Resonance Imaging/methods ; Nerve Degeneration/diagnosis ; Nerve Degeneration/etiology ; Parkinson Disease/complications ; Parkinson Disease/diagnosis ; Parkinson Disease/etiology ; Positron Emission Tomography Computed Tomography ; Synucleinopathies/complications ; Synucleinopathies/diagnosis ; Synucleinopathies/etiology
Czasopismo naukowe
Tytuł :
Automated sensor-based detection of challenging behaviors in advanced stages of dementia in nursing homes.
Autorzy :
Goerss D; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Hein A; Department of Computer Science, University of Rostock, Rostock, Germany.
Bader S; Department of Computer Science, University of Rostock, Rostock, Germany.
Halek M; German Center for Neurodegenerative Diseases (DZNE), Witten, Germany.; Faculty of Health, Witten/Herdecke University, Witten, Germany.
Kernebeck S; German Center for Neurodegenerative Diseases (DZNE), Witten, Germany.; Faculty of Health, Witten/Herdecke University, Witten, Germany.
Kutschke A; Stadtische Seniorenheime Krefeld gGmbH, Krefeld, Germany.
Heine C; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
Krueger F; Department of Computer Science, University of Rostock, Rostock, Germany.
Kirste T; Department of Computer Science, University of Rostock, Rostock, Germany.
Teipel S; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Pokaż więcej
Źródło :
Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2020 Apr; Vol. 16 (4), pp. 672-680. Date of Electronic Publication: 2020 Feb 10.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Apathy*
Dementia*/complications
Dementia*/therapy
Nursing Homes*
Aggression/*psychology
Psychomotor Agitation/*psychology
Accelerometry/statistics & numerical data ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Mental Status and Dementia Tests/statistics & numerical data
Czasopismo naukowe
Tytuł :
Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson's disease.
Autorzy :
Scheffels JF; Clinic and Polyclinic for Neurology, University Hospital Cologne, University of Cologne, Cologne, Germany.
Fröhlich L; Cologne University of Applied Sciences, faculty: Economics and Law, Cologne, Germany.
Kalbe E; Medical Psychology | Neuropsychology and Gender Studies & Centrum for Neuropsychological Diagnostics and Intervention (CeNDI), Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany. Electronic address: .
Kessler J; Clinic and Polyclinic for Neurology, University Hospital Cologne, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Journal of the neurological sciences [J Neurol Sci] 2020 May 15; Vol. 412, pp. 116735. Date of Electronic Publication: 2020 Feb 13.
Typ publikacji :
Journal Article
MeSH Terms :
Cognitive Dysfunction*/diagnosis
Cognitive Dysfunction*/etiology
Dementia*/diagnosis
Parkinson Disease*/complications
Parkinson Disease*/diagnosis
Cognition ; Germany ; Humans ; Mental Status and Dementia Tests ; Neuropsychological Tests ; Quality of Life
Czasopismo naukowe
Tytuł :
Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument.
Autorzy :
Morris GM; Department of Dermatology, St. Louis University School of Medicine.
Holden TR; Department of Medicine, Division of Geriatrics and Nutritional Science.
Weng H; Division of Biostatistics.
Xiong C; Division of Biostatistics.
Coble DW; Division of Biostatistics.
Cairns NJ; College of Medicine and Health, University of Exeter, Devon, UK.
Morris JC; Department of Neurology, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO.
Pokaż więcej
Źródło :
Alzheimer disease and associated disorders [Alzheimer Dis Assoc Disord] 2020 Apr-Jun; Vol. 34 (2), pp. 112-117.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Validation Study
MeSH Terms :
Dementia*/diagnosis
Dementia*/pathology
Neuropathology*
Predictive Value of Tests*
Mass Screening/*standards
Surveys and Questionnaires/*standards
Aged ; Aged, 80 and over ; Alzheimer Disease/diagnosis ; Alzheimer Disease/pathology ; Autopsy ; Cohort Studies ; Female ; Humans ; Longitudinal Studies ; Male ; Mental Status and Dementia Tests/statistics & numerical data ; Sensitivity and Specificity ; Surveys and Questionnaires/statistics & numerical data
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies